Trial Profile
A Multicenter, Randomized, Parallel-group, Placebo-controlled, 4-week Clinical Endpoint Bioequivalence Study Comparing Fluticasone Propionate/Salmeterol 100/50 µg Inhalation Powder With Advair® Diskus 100/50 µg in Asthma Patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Aug 2020
Price :
$35
*
At a glance
- Drugs Salmeterol/fluticasone propionate (Primary)
- Indications Asthma
- Focus Pharmacokinetics; Registrational
- Sponsors Cipla
- 02 Apr 2020 Status changed from active, no longer recruiting to completed according to a cipla media release.
- 14 Nov 2019 Planned End Date changed from 28 Feb 2020 to 31 Mar 2020.
- 14 Nov 2019 Planned primary completion date changed from 30 Dec 2019 to 3 Dec 2019.